article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

CellProthera selected the UK centres for their excellence in the conduct of clinical research with dedicated staff, equipment, availability of imaging platforms and high interest in cell therapy cardiovascular trials especially University Hospital of Birmingham equipped with a bi-plane Cathlab.

Drugs 189
article thumbnail

NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

The Pharma Data

Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers. About NANOBIOTIX: www.nanobiotix.com.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NANOBIOTIX Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3

The Pharma Data

The primary endpoint of the trial is recommended phase II dose (RP2D); the secondary endpoints are objective response rate (ORR), safety and feasibility, and body-kinetics; and the exploratory endpoints are survival outcomes, duration of response, and biomarkers of response.

article thumbnail

BioSpace Movers & Shakers, Nov. 6

The Pharma Data

Sussman has also had leadership experience in industry as the founder and vice president of both Amphioxus Cell Technologies from 1995 to 2003 and Hepatix, Inc. O’Day has been a principal investigator for more than 200 clinical trials. from 1993 to 1995. Dillon is a former St.

article thumbnail

Article FDA Thank You FDA updates set the stage for broader use of harmonized standards for safety reporting

Agency IQ

When the document was taken back to the drawing board again in 2003, it remained on hold for more than a decade until a final version was agreed upon in 2012, with the FDA officially adopting it in 2014. That revised version remains in use today ( more on this below ). This was an area that FDA investigators recently interviewed by the U.S.

FDA 40
article thumbnail

Analysis Life Sciences Thank You Roche post-approval change submission to be first test of Accumulus Synergy’s cloud platform

Agency IQ

In essence, it consists of five modules: 1) Region-specific information (essentially administrative/process-related documentation), 2) Application summary, 3) Quality information, 4) Nonclinical information, and 5) Clinical information. CMS in the United States ).

Science 40
article thumbnail

How the Fifty States View Electronic Data as a “Product”

Drug & Device Law

2003), an Internal Revenue Service regulation, excluded liability for “product” refund, repair or replacement. 23, 37 (2003) (“the phrase refers to the producer of the tangible goods that are offered for sale, and not to the author of any idea, concept, or communication embodied in those goods”). 2003), review denied (Cal.